Randomized Controlled Trial
Copyright ©The Author(s) 2018.
World J Gastroenterol. Apr 14, 2018; 24(14): 1550-1561
Published online Apr 14, 2018. doi: 10.3748/wjg.v24.i14.1550
Table 3 Recurrence rate of erosive esophagitis within 24 wk: sub-group analysis according to baseline characteristics
LPZ 15 mg
VPZ 10 mg
VPZ 20 mg
Estimate (%)1Estimate (%)1Difference2 and 95%CI (%)Fisher exact test, P value3Estimate (%)1Difference2 and 95%CI (%)Fisher exact test, P value3
Age (yr)
< 6514.4 (19/132)4.3 (6/139)-10.1 [-16.95, -3.20]0.00560.0 (0/136)-14.4 [-20.38, -8.41]< 0.0001
≥ 65 to < 7521.7 (10/46)7.0 (3/43)-14.8 [-28.91, -0.62]0.07117.0 (3/43)-14.8 [-28.91, -0.62]0.0711
≥ 7522.2 (4/18)6.7 (1/15)-15.6 [-38.54, 7.43]0.34574.5 (1/22)-17.7 [-38.76, 3.41]0.1554
Sex
Male13.9 (19/137)6.3 (10/159)-7.6 [-14.49, -0.67]0.03211.3 (2/159)-12.6 [-18.65, -6.57]< 0.0001
Female23.7 (14/59)0.0 (0/38)-23.7 [-34.58, -12.87]0.00074.8 (2/42)-19.0 [-31.59, -6.35]0.0120
Smoking classification
Never smoked22.4 (17/76)1.9 (1/54)-20.5 [-30.55, -10.48]0.00065.0 (3/60)-17.4 [-28.24, -6.50]0.0062
Current smoker20.0 (8/40)6.6 (4/61)-13.4 [-27.31, 0.42]0.05880.0 (0/57)-20.0 [-32.40, -7.60]0.0005
Ex-smoker10.0 (8/80)6.1 (5/82)-3.9 [-12.27, 4.47]0.39981.2 (1/84)-8.8 [-15.78, -1.84]0.0160
Erosive esophagitis grade4
LA Grade A/B11.0 (17/155)3.1 (5/159)-7.8 [-13.44, -2.21]0.00751.3 (2/158)-9.7 [-14.92, -4.48]0.0002
LA Grade C/D39.0 (16/41)13.2 (5/38)-25.9 [-44.26, -7.47]0.01144.7 (2/43)-34.4 [-50.58, -18.17]0.0001
CYP2C19 genotype
Extensive metabolizers19.6 (31/158)5.4 (9/166)-14.2 [-21.28, -7.11]0.00011.8 (3/168)-17.8 [-24.34, -11.33]< 0.0001
Poor metabolizers5.3 (2/38)3.2 (1/31)-2.0 [-11.48, 7.40]1.00003.0 (1/33)-2.2 [-11.43, 6.97]1.0000
H. pylori infection status
Positive3.7 (1/27)2.7 (1/37)-1.0 [-9.84, 7.83]1.00000.0 (0/27)-3.7 [-10.83, 3.42]1.0000
Negative18.9 (32/169)5.6 (9/160)-13.3 [-20.21, -6.41]0.00032.2 (4/179)-16.7 [-22.99. -10.41]< 0.0001